Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | GLS | O94925 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24501584 | 1.00 | LRRK2 (0.32) | LRRK2CNR2POLBGAAHSD11B1 | |
| SCHEMBL24501312 | 1.00 | LRRK2 (0.32) | LRRK2CNR2POLBGAAHSD11B1 | |
| SCHEMBL22717781 | 0.84 | POLB (0.40) | POLBGAAGLS | |
| SCHEMBL24501232 | 0.82 | KDM5A (0.33) | LRRK2POLBGAA | |
| SCHEMBL24501494 | 0.80 | POLB (0.47) | POLBGAAGLS | |
| SCHEMBL19449335 | 0.80 | POLB (0.44) | POLBGAAGLS | |
| SCHEMBL24500857 | 0.78 | POLB (0.35) | POLBGAA | |
| SCHEMBL24501285 | 0.77 | POLB (0.35) | POLBGAAGLS | |
| SCHEMBL24501049 | 0.76 | DHFR (0.39) | POLBGAAGLS | |
| SCHEMBL29108540 | 0.74 | FEN1 (0.35) | CNR2POLBGAAGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| CN-117083271-A | Substituted thiadiazolyl derivatives as DNA polymerase theta inhibitors | 伊迪亚生物科学有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-4255573-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022118210-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLH | LRRK2 2121/4885CNR2 4761/4885POLB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.